Stelara main patent expiration date in u.s. and eu?

Short answer: there isn’t a single “main patent expiration date” for Stelara (ustekinumab) in the U.S. or the EU. Stelara is protected by multiple patent families (covering the antibody itself, its uses, and manufacturing/formulation) plus regulatory protections (e.g., data/market exclusivities and SPCs in the EU). Because of all these layers, the effective protection period extends beyond any one patent date and can differ by country and by patent family.

If you want precise dates, I can help compile them, but I’ll need to look up the current patent families and regulatory exclusivities. To do that, I’ll need to know:
- Do you want protection for the antibody itself (composition), for specific uses (indications/methods), or for the product formulation/manufacturing?
- Are you looking for U.S. dates, EU dates, or both?

If you’d like, I can search official sources (USPTO patent data, Espacenet/EspaceNet, European Patent Register, and regulatory data exclusivity calendars) and list:
- the relevant ustekinumab patent families in the U.S. and the EU,
- their expiration dates (including any term adjustments or pediatric extensions),
- and any applicable regulatory data/approval-based exclusivities (e.g., U.S. biologics data exclusivity, EU data/market exclusivity or SPCs), with sources.